Immunic: Inaasahang data ng top-line ng Phase 3 ENSURE para sa vidofludimus calcium sa RMS sa pagtatapos ng taon 2026

Inihayag ng kumpanya na ang data ng top-line mula sa magkambal na Phase 3 ENSURE-1 at ENSURE-2 na mga pagsubok ng vidofludimus calcium sa relapsing multiple sclerosis ay inaasahan sa pagtatapos ng 2026. Ang readout na ito ang susunod na pangunahing regulatory catalyst at magbibigay-alam sa planadong NDA submission sa kalagitnaan ng 2027.

Mahahalagang fact

Na-file: Peb 26, 2026, 12:00 PM
Kaganapan: Topline na resulta
Direksyon: Neutral
Kumpanya: IMUXImmunic
Asset: vidofludimus calcium
Pinagmulan: SEC 8-K
Kumpiyansa: May source

Sipi mula sa source

EX-99.1 2 e665186_ex99-1.htm Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update – Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 – – Raised Proceeds of $200 Million in a Private Placement, with Potential for up to an Additional $200 Million – – Net Proceeds Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis and Begin of Transition into a Commercial Organization – NEW YORK, February 26, 2026 – Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financ

SEC 8-K